Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC)

References

• Hofmann WK, Stauch M, Höffken K. Impaired granulocytic function in patients with acute leukaemia: only partial normalisation after successful remission-inducing treatment. J Cancer Res Clin Oncol.1998;124(2):113–116.
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med.2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Othus M, Vainstein V, et al. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol. 2014;89(4):423–428.
   PubMed Web of Science ®Google Scholar
• Lamble AJ, Kosaka Y, Laderas T, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2020;117(25):14331–14341.
   PubMed Web of Science ®Google Scholar
• Knaus HA, Berglund S, Hackl H, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3(21):e120974.
   PubMed Web of Science ®Google Scholar
• Jia B, Zhao C, Rakszawski KL, et al. Eomes + T-bet low CD8 + T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia. Cancer Res. 2019;79(7):1635–1645.
   PubMed Web of Science ®Google Scholar
• Goswami M, Prince G, Biancotto A, et al. Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J Transl Med. 2017;15(1):155.
   PubMedGoogle Scholar
• Tang L, Wu J, Li CG, et al.Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia Clin Cancer Res 2020;26(7):1763–1772.
   PubMed Web of Science ®Google Scholar
• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
   PubMed Web of Science ®Google Scholar
• Gaertner F, Massberg S. Patrolling the vascular borders: platelets in immunity to infection and cancer. Nat Rev Immunol. 2019;19(12):747–760.
   PubMed Web of Science ®Google Scholar
• Martín Ibáñez I, Arce Casas A, Cruz Martínez O, et al. Humoral immunity in pediatric patients with acute lymphoblastic leukaemia. Allergol Immunopathol. 2003;31(6):303–310.
   PubMedGoogle Scholar
• Søegaard SH, Rostgaard K, Skogstrand K, et al. Neonatal inflammatory markers are associated with childhood B-cell precursor acute lymphoblastic leukemia. Cancer Res. 2018;78(18):5458–5463.
   PubMed Web of Science ®Google Scholar
• Idris S-Z, Hassan N, Lee L-J, et al. Increased regulatory T cells in acute lymphoblastic leukemia patients. Hematology. 2015;20(9):523–529.
   PubMed Web of Science ®Google Scholar
• Liu Y-F, Chen -Y-Y, He -Y-Y, et al. Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. J Leukoc Biol. 2017;102(2):449–458.
   PubMed Web of Science ®Google Scholar
• Flis S, Chojnacki T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther. 2019;13:825–843.
   PubMed Web of Science ®Google Scholar
• Pophali P, Horna P, Lasho TL, et al. Splenectomy in patients with chronic myelomonocytic leukemia: indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. Am J Hematol. 2018;93(11):1347–1357.
   PubMed Web of Science ®Google Scholar
• Bashford-Rogers RJ, Palser AL, Hodkinson C, et al. Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones. Exp Hematol. 2017;46(31):e10.
   Google Scholar
• Darwiche W, Gubler B, Marolleau JP, et al. Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective. Front Immunol. 2018;9:683.
   PubMed Web of Science ®Google Scholar
• Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562–572.
   PubMed Web of Science ®Google Scholar
• Arruga F, Gyau BB, Iannello A, et al. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci. 2020;21(5):1825.
   PubMed Web of Science ®Google Scholar
• Visentin A, Mauro FR, Rosati S, et al. Protective role immunoglobulin replacement therapy in chronic lymphocytic leukemia: FOCUS on subcutaneous immunoglobulin formulations. Blood. 2018;132(Supplement 1):4954.
   Google Scholar
• Morrison VA. Risk of infections in patients with chronic lymphocytic leukemia. UpToDate. Last updated: Jan 06 2020. [cited 2020 July 22]. Available from: https://www.uptodate.com/contents/risk-of-infections-in-patients-with-chronic-lymphocytic-leukemia
   Google Scholar
• Ravandi F. Hairy cell leukemia. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S254–9.
   PubMedGoogle Scholar
• Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–4404.
   PubMed Web of Science ®Google Scholar
• Li YD, Lamano JB, Lamano JB, et al. Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2019;68(9):1501–1513.
   PubMed Web of Science ®Google Scholar
• Schootman M, Jeffe DB, Ratnapradipa KL, et al. Increased 30-day mortality risk in patients with diabetes mellitus after colon cancer surgery: a mediation analysis. Dis Colon Rectum. 2020;63(3):290–299.
   PubMed Web of Science ®Google Scholar
• Danai PA, Moss M, Mannino DM, et al. The epidemiology of sepsis in patients with malignancy. Chest. 2006;129(6):1432–1440.
   PubMed Web of Science ®Google Scholar
• Te Marvelde L, Whitfield A, Shepheard J, et al. Epidemiology of sepsis in cancer patients in Victoria, Australia: a population-based study using linked data. Aust N Z J Public Health. 2020;44(1):53–58.
   PubMed Web of Science ®Google Scholar
• Akinosoglou KS, Karkoulias K, Marangos M. Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2013;17(1):8–18.
   PubMed Web of Science ®Google Scholar
• Valvani A, Martin A, Devarajan A, et al. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357.
   PubMed Web of Science ®Google Scholar
• Harikrishna J, Sukaveni V, Kumar DP, et al. Cancer and tuberculosis. JIACM. 2012;13:142–144.
   Google Scholar
• Zhang G-Q, Li Y, Ren Y-P, et al. Outcomes of preoperative endoscopic nasobiliary drainage and endoscopic retrograde biliary drainage for malignant distal biliary obstruction prior to pancreaticoduodenectomy. World J Gastroenterol. 2017;23(29):5386–5394.
   PubMed Web of Science ®Google Scholar
• Smit LC, Bruins MJ, Patijn GA, et al. Infectious complications after major abdominal cancer surgery: in search of improvable risk factors. Surg Infect. 2016;17(6):683–693.
   PubMed Web of Science ®Google Scholar
• Klaver CEL, Wasmann KATGM, Verstegen M, et al. Postoperative abdominal infections after resection of T4 colon cancer increase the risk of intra-abdominal recurrence. Eur J Surg Oncol. 2018;44(12):1880–1888.
   PubMed Web of Science ®Google Scholar
• Cilekar M, Erkasap S, Oner U, et al. An atypical cause of rapidly progressing breast lump with abscess formation: pure squamous cell carcinoma of the breast. J Cancer Res Ther. 2015;11(4):1023.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(Suppl 5):v111–v118.
   PubMed Web of Science ®Google Scholar
• Kochanek M, Schalk E, von Bergwelt-baildon M, et al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the infectious diseases working party (AGIHO) and intensive care working party (ICHOP) of the German society of hematology and medical oncology (DGHO). Ann Hematol. 2019;98(5):1051–1069.
   PubMed Web of Science ®Google Scholar
• Knight T, Ahn S, Rice TW, et al. Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. Eur J Intern Med. 2017;45:59–65.
   PubMed Web of Science ®Google Scholar
• Friefeld A, Bow E, Sepkowitz K, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Connell B, Byrne D, et al. Prognostic value of blood cultures as an illness severity marker in emergency medical admissions. Acute Med. 2020;19(2):83–89.
   PubMedGoogle Scholar
• Cooksley T, Rice T. Emergency oncology: development, current position and future direction in the USA and UK. Support Care Cancer. 2017;25(1):3–7.
   PubMed Web of Science ®Google Scholar
• Koenig C, Schneider C, Morgan JE, et al. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer. 2020;28(3):1369–1383.
   PubMed Web of Science ®Google Scholar
• Mattison G, Bilney M, Haji-Michael P, et al. A nurse-led protocol improves the time to first dose intravenous antibiotics in septic patients post chemotherapy. Support Care Cancer. 2016;24(12):5001–5005.
   PubMed Web of Science ®Google Scholar
• Botten J, Beard J, Zorzi A, et al. A simple intervention to improve antibiotic treatment times for neutropenic sepsis. Acute Med. 2016;15(1):3–6.
   PubMedGoogle Scholar
• Walker S, Grigg S, Kirkpatrick C, et al. Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia. Support Care Cancer. 2020;28(9):4337–4343.
   PubMed Web of Science ®Google Scholar
• Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003; (3):CD003038. doi:10.1002/14651858.CD003038.
   PubMedGoogle Scholar
• Angus D, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–851.
   PubMed Web of Science ®Google Scholar
• Dellinger R, Levy M, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637.
   PubMed Web of Science ®Google Scholar
• McMenamin L, Murch N, Daniels R. Severe sepsis, social media and the #sepsis 6: ‘Tweeting’ national innovations. Acute Med. 2013;12(2):83–88.
   PubMedGoogle Scholar
• Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808.
   PubMed Web of Science ®Google Scholar
• Annane D, Renault A, Brun-Buisson C, et al. CRICS-TRIGGERSEP Network Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–818.
   PubMed Web of Science ®Google Scholar
• Clark O, Lyman G, Castro A, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214.
   PubMed Web of Science ®Google Scholar
• Karlin L, Darmon M, Thiéry G, et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant. 2005;36(3):245–250.
   PubMed Web of Science ®Google Scholar
• Lemiale V, Pons S, Mirouse A, et al. Sepsis and septic shock in patients with malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique study. Crit Care Med. 2020;48(6):822–829.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Haji-Michael P. Oncologic sepsis on the ICU: two decades of improving outcomes. Crit Care Med. 2020;48(6):925–926.
   PubMed Web of Science ®Google Scholar
• Vincent F, Soares M, Mokart D, et al. In-hospital and day-120 survival of critically ill solid cancer patients after discharge of the intensive care units: results of a retrospective multicenter study—A Groupe de recherche respiratoire en réanimation en Onco–Hématologie (Grrr-OH) study. Ann Intensive Care. 2018;8(1):40.
   PubMed Web of Science ®Google Scholar
• Murphy K, Cooksley T, Haji-Michael P. Short- and long-term outcomes of patients with solid tumours following non-surgical intensive care admission. QJM. 2018;111(6):379–383.
   PubMed Web of Science ®Google Scholar
• Ma W, Saif M, El-Rayes B, et al. Emergency use of Uridine Triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123(2):345–356.
   PubMed Web of Science ®Google Scholar
• Chen K, Wang Q, Pleasants RA, et al. Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis. 2017;17:159.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Teschner D, Maschmeyer G, et al. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev Anti Infect Ther. 2019;17(12):983–995.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487–1495.
   PubMed Web of Science ®Google Scholar
• Teuffel O, Ethier M, Alibhai S, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011;22(11):2358–2365.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Holland M, Klastersky J. Ambulatory Outpatient Management of patients with low risk febrile neutropaenia. Acute Med. 2015;14(4):178–181.
   PubMedGoogle Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18: 3038–3051.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36: 1443–1453.
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465–471.
   PubMed Web of Science ®Google Scholar
• Ahn S, Rice TW, Yeung SJ, et al. Comparison of the MASCC and CISNE scores for identifying low risk neutropenic fever patients: analysis of data from three emergency departments in cancer centers in three continents. Support Care Cancer. 2018;26(5):1465–1470.
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T, et al., A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 341(5): 305–311. 1999.
   PubMed Web of Science ®Google Scholar
• Kern W, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicentre trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy – EORTC Infectious Diseases Group trial XV. J Clin Oncol. 2013;31(9):1149–1156.
   PubMed Web of Science ®Google Scholar
• Lasserson DS, Harris C, Elias T, et al. What is the evidence base for ambulatory care for acute medical illness? Acute Med. 2018;17(3):148–153.
   PubMedGoogle Scholar
• Cooksley T, Marshall W, Ahn S, et al. Ambulatory emergency oncology: A key tenet of future emergency oncology care. Int J Clin Pract. 2020;74(1):e13436.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Campbell G, Al-Sayed T, et al. A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) Clinic. Support Care Cancer. 2018;26(9):2937–2940.
   PubMed Web of Science ®Google Scholar
• Marshall W, Campbell G, Knight T, et al. Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits—real-world experience from a UK cancer center. J Emerg Med. 2020;58(3):444–448.
   PubMed Web of Science ®Google Scholar
• Marshall E. Ambulatory management in low risk neutropenic sepsis – A plea for integrated acute cancer care. Acute Med. 2019;18:5–6.
   Google Scholar
• Tew M, Forster D, Teh BW, et al. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia. Aust Health Rev. 2019;43(5):549–555.
   PubMed Web of Science ®Google Scholar
• Brunner C, Botten J, Wennike N, et al. Early Supported Discharge for patients with febrile neutropenia - Experience at a large district hospital in the UK. Acute Med. 2019;18(1):14–19.
   PubMedGoogle Scholar
• Teh BW, Brown C, Joyce T, et al. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer. 2018;26(3):997–1003.
   PubMed Web of Science ®Google Scholar
• Berman R, Davies A, Cooksley T, et al. Supportive Care: an indispensable component of modern oncology. Clin Oncol (R Coll Radiol). 2020;32(11):781–788.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Armitage JO. Recommendations for the use of white blood cell growth factors: american society of clinical oncology clinical practice guideline update. J Oncol Pract. 2015;11(6):511–513.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hematopoietic Growth Factors Version 2.2020 — january 27, 2020 https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.Lastaccessed06-September2020.
   Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109–118.
   PubMedGoogle Scholar
• Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thoracic Soc. 2014;11(3):404–406.
   PubMedGoogle Scholar
• Sattar SBA, Sharma S. Bacterial Pneumonia. StatPearls Publishing LLC. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020; 2020. Bookshelf ID: NBK513321
   Google Scholar
• Pahal P, Rajasurya V, Sharma S. Typical Bacterial Pneumonia. StatPearls Publishing LLC. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020; 2020. Bookshelf ID: NBK513321
   Google Scholar
• Pletz MW, Blasi F, Chalmers JD, et al., International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest. 158(5): 1912–1918. 2020.
   PubMed Web of Science ®Google Scholar
• Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619–1628.
   PubMed Web of Science ®Google Scholar
• Garcia JB, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thoracic Soc. 2013;10(5):432–440.
   PubMedGoogle Scholar
• Rossini F, Verga M, Pioltelli P, et al. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens. Haematologica. 2000;85(12):1255–1260.
   PubMed Web of Science ®Google Scholar
• Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: analysis of the acute leukemia french association-9802 prospective multicenter clinical trial. Leuk Lymphoma. 2012;53(6):1068–1076.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Breuer R, Or R, et al. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study. Transplantation. 1995;60(7):672–678.
   PubMed Web of Science ®Google Scholar
• Roychowdhury M, Pambuccian SE, Aslan DL, et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med. 2005;129(3):366–371.
   PubMed Web of Science ®Google Scholar
• Specchia G, Pastore D, Carluccio P, et al. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma. 2003;44(1):97–101.
   PubMed Web of Science ®Google Scholar
• Chang H-Y, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. Medicine (Baltimore). 1976;55(3):259–268.
   PubMed Web of Science ®Google Scholar
• White DA. Pulmonary infection in the immunocompromised patient. Semin Thorac Cardiovasc Surg. 1995;7(2):78–87.
   PubMedGoogle Scholar
• Dickson RP, Erb-Downward JR, Martinez FJ, et al. The microbiome and the respiratory tract. Ann Rev Physiol. 2016;78(1):481–504.
   PubMedGoogle Scholar
• Dickson RP, Morris A. Macrolides, inflammation and the lung microbiome: untangling the web of causality. Thorax. 2017;72(1):10–12.
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017;10(2):299–306.
   PubMed Web of Science ®Google Scholar
• Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev. 2018;98(3):1417–1464.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415–427.
   PubMed Web of Science ®Google Scholar
• Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817–823.
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Community-acquired pneumonia. Int J Clin Pract Suppl. 2000; Dec;(115):18–22.
   Google Scholar
• Harrington RD, Woolfrey AE, Bowden R, et al. Legionellosis in a bone marrow transplant center. Bone Marrow Transplant. 1996;18(2):361–368.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Aoun M. Opportunistic infections in patients with cancer. Ann Oncol. 2004;15(Suppl 4):iv329–335.
   PubMedGoogle Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361–370.
   PubMed Web of Science ®Google Scholar
• Mulanovich VE, Kontoyiannis DP. Fungal pneumonia in patients with hematologic malignancies: current approach and management. Curr Opin Infect Dis. 2011;24(4):323–332.
   PubMed Web of Science ®Google Scholar
• Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am. 2010;24(2):439–459.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–1360.
   PubMed Web of Science ®Google Scholar
• Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis. 2008;10(3):162–167.
   PubMed Web of Science ®Google Scholar
• Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29(6):1467–1471.
   PubMed Web of Science ®Google Scholar
• Evans RA, Clifford TM, Tang S, et al. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation. Transpl Infect Dis. 2015;17(6):816–821.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). J Antimicrob Chemother. 2016;71(9):2397–2404.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis. 2002;34(3):400–403.
   PubMed Web of Science ®Google Scholar
• Rolston KVI. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13(4):218–223.
   PubMed Web of Science ®Google Scholar
• Ljungman P. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation. Curr Opin Hematol. 2014;21(6):466–469.
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–2729.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78–83.
   PubMed Web of Science ®Google Scholar
• Chen D, Patel RR, Verma V, et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 2020;150:114–120.
   PubMedGoogle Scholar
• Schiffer JT, Kirby K, Sandmaier B, et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101–1108.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol. 2002;119(4):1125–1132.
   PubMed Web of Science ®Google Scholar
• Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195(8):1126–1136.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the european group for blood and marrow transplantation. Bone Marrow Transplant. 2001;28(5):479–484.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119(12):2738–2745. quiz 2969.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Shah DP, Kmeid J, et al. Burden of human metapneumovirus infections in patients with cancer: risk factors and outcomes. Cancer. 2017;123(12):2329–2337.
   PubMed Web of Science ®Google Scholar
• Shah DP, Ghantoji SS, Mulanovich VE, et al. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res. 2012;2(4):203–218.
   PubMedGoogle Scholar
• Torres HA, Aguilera E, Safdar A, et al. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case–control study. Clin Microbiol Infect. 2008;14(12):1160–1166.
   PubMed Web of Science ®Google Scholar
• Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143(4):455–467.
   PubMed Web of Science ®Google Scholar
• Shafagati N, Williams J. Human metapneumovirus - what we know now. F1000Res. 2018;7:135.
   PubMedGoogle Scholar
• Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001;27(8):877–881.
   PubMed Web of Science ®Google Scholar
• Fishman JA. Infection in Organ Transplantation. Am J Transplant. 2017;17(4):856–879.
   PubMed Web of Science ®Google Scholar
• Rolston KVI. Infections in cancer patients with solid tumors: a Review. Infect Dis Ther. 2017;6(1):69–83.
   PubMed Web of Science ®Google Scholar
• Werbel WA, Ison MG, Angarone MP, et al. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis. 2018;20(3):e12876.
   PubMed Web of Science ®Google Scholar
• De La Rosa GR, Jacobson KL, Rolston KV, et al. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990–2000. Clin Microbiol Infect. 2004;10(8):749–752.
   PubMed Web of Science ®Google Scholar
• Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France. Emerg Infect Dis. 2014;20(9):1490–1497.
   PubMed Web of Science ®Google Scholar
• Fishman JA, Gans H. Pneumocystis jiroveci in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13587.
   PubMedGoogle Scholar
• Shannon VR. Pneumotoxicity associated with immune checkpoint inhibitor therapies. Curr Opin Pulm Med. 2017;23(4):305–316.
   PubMed Web of Science ®Google Scholar
• Shannon VR, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer. 2020;28(12):6145–6157.
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994;18(4):501–513.
   PubMed Web of Science ®Google Scholar
• Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Clin Proc. 2005;80(11):1414–1420.
   Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of america. Am J Respir Crit Care Med. 2019;200(7):e45–e67.
   PubMed Web of Science ®Google Scholar
• Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(4):647–655.
   PubMed Web of Science ®Google Scholar
• Lynn -J-J, Chen K-F, Weng Y-M, et al. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol. 2013;31(4):189–196.
   PubMed Web of Science ®Google Scholar
• Al-Qadi MO, Cartin-Ceba R, Kashyap R, et al. The diagnostic yield, safety, and impact of flexible bronchoscopy in non-HIV immunocompromised critically ill patients in the intensive care unit. Lung. 2018;196(6):729–736.
   PubMed Web of Science ®Google Scholar
• Hamade B, Huang DT. Procalcitonin: where are we now? Critical Care Clinics. 2020;36(1):23–40.
   PubMed Web of Science ®Google Scholar
• Karakioulaki M, Stolz D. Biomarkers in Pneumonia—Beyond Procalcitonin. Int J Mol Sci. 2019;20(8):2004.
   PubMed Web of Science ®Google Scholar
• Wussler D, Kozhuharov N, Tavares Oliveira M, et al. Clinical utility of procalcitonin in the diagnosis of pneumonia. Clin Chem. 2019;65(12):1532–1542.
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses. 2007;50(Suppl s1):2–17.
   PubMedGoogle Scholar
• Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50(3):1051–1053.
   PubMed Web of Science ®Google Scholar
• Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47(4):877–884.
   PubMed Web of Science ®Google Scholar
• Huang YT, Hung CC, Hsueh PR. Aspergillus galactomannan antigenemia in penicilliosis marneffei. Aids. 2007;21(14):1990–1991.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54(5):633–643.
   PubMed Web of Science ®Google Scholar
• Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65(6):510–515.
   PubMed Web of Science ®Google Scholar
• Louie JK, Yang S, Yen C, et al. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One. 2012;7(6):e40261.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
   PubMed Web of Science ®Google Scholar
• Haydour Q, Hage CA, Carmona EM, et al. Diagnosis of fungal infections. a systematic review and meta-analysis supporting american thoracic society practice guideline. Ann Am Thorac Soc. 2019;16(9):1179–1188.
   PubMed Web of Science ®Google Scholar
• Limper AH, Knox KS, Sarosi GA, et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;2014:CD008965.
   Google Scholar
• Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res. 2017;146:12–20.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Park SB, et al. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One. 2015;10(4):e0122642.
   PubMed Web of Science ®Google Scholar
• Lamont RF, Sobel JD, Carrington D, et al. Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG. 2011;118(10):1155–1162.
   PubMed Web of Science ®Google Scholar
• Schutte TJ, Rogers LC, Copas PR. Varicella pneumonia complicating pregnancy: a report of seven cases. Infect Dis Obstet Gynecol. 1996;4(6):338–346.
   PubMedGoogle Scholar
• Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30(6):554–561.
   PubMed Web of Science ®Google Scholar
• Hui DS, Lee N, Chan PK, et al. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018;150:202–216.
   PubMed Web of Science ®Google Scholar
• Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2:CD010406.
   PubMedGoogle Scholar
• Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12:CD007720.
   PubMedGoogle Scholar
• Chowdhury IH, Ahmed AM, Choudhuri S, et al. Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy. Mol Immunol. 2014;62(1):159–168.
   PubMed Web of Science ®Google Scholar
• Zumla A, Rao M, Parida SK, et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med. 2015;277(4):373–387.
   PubMed Web of Science ®Google Scholar
• Crowle AJ, Ross EJ. Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun. 1989;57(3):840–844.
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE, Dorhoi A, Hotchkiss RS, et al. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17:35–56.
   PubMed Web of Science ®Google Scholar
• Davis JS, Ferreira D, Paige E, et al. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33:e00035–19.
   PubMed Web of Science ®Google Scholar
• Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597–1605.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Pradier O, Hotchkiss RS, et al. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18.
   PubMed Web of Science ®Google Scholar
• Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25(8):1243–1250.
   PubMed Web of Science ®Google Scholar
• Tezera LB, Bielecka MK, Ogongo P, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. Elife. 2020;9:e52668.
   PubMed Web of Science ®Google Scholar
• Anastasopoulou A, Ziogas DC, Samarkos M, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019;7(1):239.
   PubMed Web of Science ®Google Scholar
• Del Castillo M, Romero FA, Argüello E, et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490–1493.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Corrections to “Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264–iv266.
   PubMedGoogle Scholar
• Rapoport BL, Anderson R, Cooksley T, et al. MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer. 2020;28(12):6107–6110.
   PubMed Web of Science ®Google Scholar
• Blidner AG, Choi J, Cooksley T, et al. Cancer immunotherapy–related adverse events: causes and challenges. Support Care Cancer. 2020;28(12):6111–6117.
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Pundole X, Abdel-Wahab N, et al. Multinational Association of Supportive Care Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28(12):6159–6173.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Stutman R, Klotz A. Emergency management of immune-related toxicity. Curr Opin Oncol. 2020;32(4):274–281.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Gupta A, Al-Sayed T, et al. Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020;130:193–197.
   PubMed Web of Science ®Google Scholar
• Barbacki A, Maliha P, Hudson M, et al. A case of severe Pembrolizumab-induced neutropenia. Anti-Cancer Drugs. 2018;29(8):817–819.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–1766.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248–255.
   PubMedGoogle Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;33(10):2527–2530.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–3397.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003;9(3):976–980.
   PubMed Web of Science ®Google Scholar
• Seiter K, Latremouille-Viau D, Guerin A, et al. Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States. Adv Ther. 2018;35(10):1671–1685.
   PubMed Web of Science ®Google Scholar
• Grávalos C, Sanmartín O, Gúrpide A, et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the spanish academy of dermatology and venereology and the spanish society of medical oncology. Clin Transl Oncol. 2019;21(5):556–571.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ran Y, Shao Y, et al. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(1):33–40.
   PubMed Web of Science ®Google Scholar
• Qi WX, Fu S, Zhang Q, et al. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. Crit Rev Oncol Hematol. 2015;94(3):323–336.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
   PubMed Web of Science ®Google Scholar
• Sarnaik A, Khushalani N, Chesney J, et al. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. J Clin Oncol. 2020;38(15_suppl):10006. doi. 10.1200/JCO.2020.38.15_suppl.10006.
   Web of Science ®Google Scholar